Corix Bioscience Overview
Get informed when a big investor buys or sells
+ Follow-86.82%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for CXBS is -86.82%. That is below the sector sector average of 11.64%. Investors often review this figure alongside Corix Bioscience's historical trend and sector peers before judging valuation or financial health.
Against its sector companies, CXBS currently prints -86.82% for ROE, while the sector average sits near 11.64%. That is roughly 846.1% below the sector mean. Large gaps often invite a closer look at Corix Bioscience's growth, margins, and balance sheet.
Return on Equity shows how effectively Corix Bioscience converts resources into returns. At -86.82%, CXBS may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting CXBS's ROE (-86.82%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
